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Synopsis: 
Gene delivery vectors that do not rely on host cell genome integration offer a number of 
advantages for gene transfer, chiefly the avoidance of insertional mutagenesis and position 
effect variegation. However, unless engineered for replication and segregation, non-
integrating vectors will dilute progressively in proliferating cells, and are not exempt of 
epigenetic effects. Here we provide an overview of the main non-integrating viral 
(adenoviral, adeno-associated viral, integration-deficient retro/lentiviral, poxviral) and non-
viral (plasmid vectors, artificial chromosomes) vectors used for pre-clinical and clinical cell 
and gene therapy applications. We place particular emphasis on their utilisation for 
hematologic disease indications. 
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Key points:  
• Host cell genome integration of first-generation gene therapy vectors may result in 
various effects on cellular genes (knockout, over-expression, altered splicing), 
variegated levels of transgene expression or transcriptional silencing, as well as clonal 
expansion and oncogenic transformation. 
• Non-integrating gene therapy vectors can be viral and non-viral. Viral vectors can be 
non-integrating like their parental organisms (adenovirus, herpesvirus, poxvirus, 
Sendai) or engineered to minimise integration (adeno-associated virus, 
retro/lentivirus). 
• Non-integrating vectors can provide stable transgene expression in quiescent cells 
and transient or stable expression in proliferating cells. 
• Variants of non-integrating vectors carrying suitable payloads (transposons, site-
specific recombination cassettes, genome editing cassettes) are suitable platforms 
for genetic modification of the cellular genome by transposition, site-directed 
integration and genome editing. 
• Successful clinical trials have already been reported using adenoviral vectors 
(genome editing of CCR5 for AIDS), herpesvirus vectors (cancer) and adeno-
associated virus vectors (hemophilia).  
Non-integrating Gene Therapy Vectors 
Brief historical overview of gene therapy 
The concept of gene therapy arose during the 1960s and early 1970s. Rogers carried out the 
first genetic modification of a virus (Tobacco mosaic virus, TMV), and proposed in 1970 that 
"good DNA" could be used to replace defective DNA in people afflicted by genetic disorders1. 
In 1972, Friedmann and Roblin assessed the requirements and risks and called for a 
moratorium2. An unsuccessful early attempt at gene therapy was reported in the scientific 
literature in 19753. The first patient with some degree of long-term transgene persistence 
from a gene therapy clinical trial was in adenosine deaminase severe combined 
immunodeficiency (ADA-SCID), following an autologous transplant of T-cells treated ex vivo 
with an integration-proficient retroviral vector, initiated in 1990 and reported in 19954. The 
first clear success was published by the group of Fischer in 2000, describing the treatment of 
X-linked severe combined immunodeficiency (SCID-X1) patients with autologous 
hematopoietic stem/progenitor cells (HSPC) genetically modified with similar retroviral 
technology5. These efforts with integrative retroviral vectors led to the approval of 
StrimvelisTM in Europe for the treatment of patients with ADA-SCID for whom no suitable 
human leukocyte antigen (HLA)-matched stem cell donor is available.  
Despite the initial success with integrating vectors, non-integrating viral vectors were the 
first approved products for cell and gene therapies in China and Europe. Onyx-015©6 
(originally named Ad2/5 dl1520), an experimental oncolytic adenoviral (Ad) vector trialled as 
a possible treatment for head and neck cancer, was the first gene therapy product licensed, 
in China in 2006, under the name H101©7. An adeno-associated viral (AAV) vector, Glybera® 
(uniQure/Chiesi)8, was subsequently approved by EMA in 2012 as the first gene therapy in 
Europe, for lipoprotein lipase deficiency. An oncolytic herpes simplex virus-1 (HSV-1; 
IMLYGIC®, Amgen)9, was approved in 2015 for the treatment of advanced melanoma by both 
FDA and EMA.  
Non-integrating vectors 
Optimal vectors for gene delivery should exhibit high payload capacity, cell tropism for 
specific target cell types, high transduction efficiency, little or no geno- and cytotoxicity, and 
should elicit minimal or no immune response. Non integrating vectors specifically share 
reduced risk of genotoxicity, offering a safer profile in vivo and in vitro, and expression can 
be retained for long periods in post-mitotic tissues. However, unless they have been 
specifically genetically engineered for replication and segregation, non-integrating vectors 
will dilute progressively in proliferating cells. If stable expression in dividing cells is required, 
repeated administration of non-integrating vectors is an option, provided that an immune 
response can be avoided or managed.  
Here we provide an overview of the main non-integrating viral vectors: Ad, AAV, integration-
deficient lentiviral vectors (IDLVs), poxviral and others. Non-viral vectors (plasmid, artificial 
chromosomes) will also be discussed. We illustrate the structure of the main non-integrating 
viral vectors (Fig. 1), and summarise the use of non-integrating vectors in clinical trials (Table 
1). Different vector systems provide a variety of advantageous properties and challenges 
(Table 2). Traditionally, viral vectors are considered more efficient while non-viral methods 
have advantages in terms of large-scale production and low immunogenicity.  
 
Non-Integrating Viral Vectors 
Adenovirus vectors 
Adenovirus vectors key features: 
• Efficient delivery to dividing & non-dividing cells.  
• Retained as non-integrated nuclear linear episomes. 
• High but transient expression. 
• High immunogenicity. 
• ~8-30kb capacity. 
Adenoviruses are a family of DNA viruses with an icosahedral, 70-100nm in diameter, non-
enveloped capsid engulfing a double-stranded (ds) DNA genome. These viruses can infect 
quiescent and dividing cells and replicate in the cell nucleus. Ad vectors were used early in 
clinical trials of cystic fibrosis, in various cancer types and in more recent clinical trials of 
peripheral vascular and coronary artery disease10. Serotypes 2 and 5 are the most 
extensively characterised human Ad serotypes from a range of >50 Ad subdivisions/clades, 
with a typical Ad5 vector genome of ~36kb encoding genes that are expressed before (Early, 
E) and after (Late, L) viral replication. Early transcription units encode proteins required for 
viral transactivation and host-virus interactions. >30 novel non-human primate (NHP) 
adenoviruses from chimpanzees, bonobos and gorillas and various other species such as 
canine, equine etc have been isolated and characterised.  
Conventional Ad vectors were constructed by substituting the E1 region of the adenovirus 
genome with the transgene cassette of interest [E1-] (Fig. 1A,B). Thus, first generation Ad 
vectors [E1-] had a carrying capacity of <8kB. However, other viral genes are expressed and 
Ad capsid proteins appear to activate innate host immune responses that within 2 weeks can 
result in the loss of Ad transduced cells11. Different combinations of early region Ad 
deletions have been tested providing the Ad vector with modified properties and allowing 
for enhanced duration of transgene expression. Subsequent generations of adenoviral 
vectors were characterised by deletions of E1 and E2 and /or E4 genes, although toxicity 
from an E1/E4 deleted Ad vector lead to the first reported fatality in the field of gene 
therapy12. Ad vectors with multiple backbone deletions also reduce the risk of generation of 
replication competent adenoviral (RCA) particles. Latest generations of ‘gutless’ helper-
dependent (HD) Ad vectors are devoid of most viral sequences, minimally retaining only the 
viral ITRs, and the packaging recognition signal. They can accommodate up to 28-32kb 
foreign exogenous DNA sequences and have been used in various pre-clinical animal studies 
with apparent stable expression and low levels of toxicity13. Hence, HD Ad vectors appear to 
have significant advantages over 1st generation Ad vectors. However, it should be noted 
that production of HD Ad is considerably more challenging. 
Neutralising Abs and pre-existing immunity (discussed also in the AAV vector section of this 
review) represent a significant barrier to repeated vector administration, a strategy of 
potential importance with episomally maintained vectors. Low-level expression of viral 
vector genes in such settings almost always results in the generation of immune responses 
directed against Ad-transduced cells and ultimately in loss of transgene expression. Latest-
generation HD-Ad vectors represent a significant advantage, but it is possible that they may 
still potentiate cytotoxic T-cell responses even in the absence of de novo viral gene 
expression. However, repeated administration using HD-Ad vectors of different serotypes 
has been achieved14. 
Future directions and hematopoietic application 
Current Ad vectors are primarily derived from common serotypes 2 and 5. There are now 
efforts, however, to exploit other human/nonhuman adenoviral serotypes or 
mosaic/chimeric/hybrid15 adenoviruses to avoid administration problems associated with 
pre-existing immunity and transduction longevity issues. Approaches targeting uncontrolled 
blood thrombogenesis by systemically over-expressing prothrombin via Ad vector-mediated 
gene transfer have been explored16. Efficient genome editing in HSPC with helper-dependent 
Ad5/35 vectors expressing site-specific endonucleases, under microRNA regulation, can be a 
useful tool for therapeutic purposes17. 
 
Adeno-associated virus vectors 
Adeno-associated virus vectors key features: 
• Efficient delivery to dividing and non-dividing cells. 
• ~4.5 kb cloning capacity. 
• Capable of sustained expression as episomal concatemers in post-mitotic tissues. 
• Relatively low immunogenicity. 
AAV is a human defective parvovirus whose 4.7 kb single-stranded (ss) genome is flanked by 
two inverted terminal repeats (ITRs) and comprises of two genes, rep and cap. rep encodes 
for non-structural (replication) proteins, and is also important for site-specific integration 
into AAVS118 (Fig. 1C,D). cap encodes for structural (encapsidation) proteins, and the 
accessory assembly-activating protein (AAP), essential for serotype-specific assembly. In 
recombinant AAV vectors the viral backbone segment including the rep and cap genes is 
removed and supplied in trans. The ITRs are the most prominent genomic characteristic of 
the virus; they consist of a 125 nucleotide-long palindromic hairpin structure and a 20 
nucleotide stretch, designated as the D-sequence, which remains single-stranded. The ITRs 
contain recognition signals for replication, packaging into functional virions and integration. 
Efficient replication and lytic growth of AAV depends on co-infection by a helper virus. Ads, 
HSV type I/II, pseudorabies virus and cytomegalovirus can provide complete helper functions 
for AAV replication. 
Wild-type (wt)-AAV2 preferentially integrates into the AAVS1 site, in the long arm of human 
chromosome 19 (19q13.3-qter), in a process mediated by rep binding18. In addition, more 
than 20 alternative integration sites have been identified19. The absence of obvious 
pathogenic effects of AAV integration into AAVS1 has led to the development of this site as a 
safe-harbour locus for multiple applications. However, recombinant AAV vectors fail to 
integrate in the absence of rep protein and instead essentially become non-integrating 
vectors, able to impart long-term episomal persistence in post-mitotic tissues like muscle. 
Mostly they are maintained as large head-to-tail circularized multimeric concatemer 
structures, with a common structural element including a complete ITR flanked by two D-
region elements. The generation of such concatemers may involve recombination and a 
possible rolling circle-type DNA replication mechanism20. 
More than 170 (7.2%) of human trials have utilized AAV vectors (clinical studies available as 
of August 2016; Table 1). The low immunological response to AAV-mediated gene transfer 
was initially attributed to limited transduction of antigen-presenting dendritic cells, although 
further data demonstrated the ability of AAV to transduce immature dendritic cell 
populations21 and provoke humoral immune responses. At least 12 naturally isolated AAV 
serotypes have been identified to date. In addition, a wide range of mosaic/hybrid and novel 
capsids generated by de novo shuffling approaches are rapidly expanding the current AAV 
toolbox22. This is important, as different serotypes display varying tropism, and because 
dose-escalation of recombinant AAV-2 in clinical trials may have caused acute inflammatory 
responses to viral coat proteins similar to the ones encountered in Ad trials. The use and 
combination of various AAV serotypes provides flexibility, low-immunogenicity, possible 
differential antigenic display and lack of antibody cross-reactivity. A detailed understanding 
of the tropism of AAV serotypes is playing a key role in transduction studies and clinical 
trials23. 
Future directions and hematopoietic application 
The field of AAV gene therapy has progressed rapidly over the past decade, with the advent 
of novel capsid serotypes, organ-specific promoters and an increasing understanding of the 
immune response to AAV administration24. Recently, utilising non-biased haploid/knockout 
genetic screening approaches, AAVR has been identified as a universal host receptor for 
AAV-2 infections25. New AAV isolates, particularly AAVHSCs, represent a new class of genetic 
vectors that may be particularly suited for the manipulation of HSPC26. 
In a clinical setting, as discussed extensively elsewhere in this issue, peripheral-vein infusion 
of scAAV2/8-LP1-hFIXco (codon-optimised factor IX gene targeted to the liver) resulted in FIX 
transgene expression at levels sufficient to improve the bleeding haemophilia B phenotype, 
with few side effects27. Following on from these studies, there are now three ongoing trials 
(with more under way) of AAV-mediated gene transfer in haemophilia B, all aiming to 
express the factor IX gene from the liver28. Additionally, AAV liver expression of the 
hyperactive variant FIX-Padua prevented and eradicated FIX inhibitor without increasing 
uncontrolled thrombogenesis in hemophilia B dogs and mice, supporting the potential 
translation of gene-based strategies using FIX-Padua at lower vector doses29. Recently, 
preliminary data from infused participants in an ongoing Phase 1/2 clinical trial of FIX-Padua-
containing AAV vector (SPK-9001) for hemophilia B have been released. Following a single 
administration of 5 x 1011 vector genomes (vg)/kg, all participants experienced consistent 
and sustained (~30% in average) increases in factor IX activity30. Developments of relevance 
to other forms of hemophilia are also in the pipeline. Liver-directed gene therapy with AAV-
FVIII in two outbred dogs with severe hemophilia A resulted in sustained expression of 1-2% 
of normal FVIII levels and prevented 90% of expected bleeding episodes31. Engineering of 
factor VIII to reduce its size and facilitate its delivery with AAV vectors has recently shown 
success in interim results from a clinical trial. B-domain deleted FVIII construct was 
administered in an AAV5 vector (BMN 270) to subjects with severe hemophilia A. High-dose 
(6 x 1013 vg/kg) subjects required no further FVIII prophylactic post-BMN 270 infusion32. 
Codon optimization of human FVII (hFVIIcoop) improved AAV transgene expression by 37-
fold compared with the wild-type hFVII cDNA, whereas in the same study, in adult 
macaques, a single peripheral vein injection of 2 x 1011 vg/kg of the hFVIIcoop AAV vector 
resulted in therapeutic levels of hFVII expression33. Regarding other diseases, AAV has also 
been used in a murine model of thrombotic thrombocytopenic purpura (TTP), which is 
caused by severe deficiency of plasma ADAMTS13 activity. Current treatment of hereditary 
TTP is through plasma infusions. AAV8-hAAT-mdtcs (expressing MDTCS, a C-terminus 
truncated variant of ADAMTS13, driven by the liver-specific alpha-1 anti-trypsin promoter) at 
doses greater than 2.6 x 1011 vg/kg body weight (which were required to achieve therapeutic 
levels of ADAMTS13 plasma/antigen activity and were comparable with those reported for 
haemophilia B studies) resulted in sustained expression of plasma ADAMTS13 activity at 
therapeutic levels34. Separately, AAV is also a very promising tool for genome editing, both 
for delivery of chimeric nucleases and repair template in culture and in vivo35. 
 
Integration-deficient lentiviral vectors (IDLVs) 
Integration-deficient lentiviral vectors key features: 
• Generated through the use of mutations in the integrase gene. 
• ~7.5 kb capacity for foreign DNA. 
• Efficient delivery to dividing and non-dividing cells. 
• Transient expression in proliferating cells and sustained expression in post-mitotic 
tissues. 
• Relatively low immunogenicity. 
Retroviruses are single-stranded RNA viruses whose genome is reverse transcribed into 
double-stranded DNA and integrated into the infected cell genome. Genomic integration 
leads to stable maintenance and potentially sustained expression. These features are kept in 
retroviral vectors, which makes them particularly appreciated when stable, long-term 
expression is sought. The lentivirus genus of retroviruses includes species with a more 
complex genome, which in addition to genes gag, pol and env features a variable array of 
accessory genes36. Lentiviruses offer additional tropism as they are able to infect quiescent 
as well as dividing cells, the former not being suitable targets for classical gamma 
retroviruses. Lentiviruses infecting various mammals have been converted into lentiviral 
vectors, but the most used are those based on HIV-137 (Fig. 1E,F). Vectors based upon equine 
infectious anaemia virus (EIAV) are also highly engineered and have been developed for 
commercial use38. Both HIV-1 and EIAV vectors have been used successfully for transduction 
of the central nervous system (CNS)37,38. 
Several strategies have been implemented to improve the bio-safety of lentiviral vectors. 
These vectors do not encode any viral product, as the viral proteins are provided in trans 
from several packaging plasmids to split the original viral genome. Accessory genes, often 
responsible for pathogenic features, have been progressively removed from the production 
system39. Vectors have also been made self-inactivating (SIN) by deleting the transcriptional 
promoter/enhancer from the 3’ LTR in the transfer plasmid; this deletion is copied onto the 
5’ end of the vector during the reverse transcription cycle, abolishing expression from the 
viral LTR. SIN vectors are therefore dependent on an internal promoter to provide transgenic 
expression40.  
The theoretical risk from insertional mutagenesis mediated by retroviral vectors 
unfortunately first materialised in SCID-X1 clinical trials, where ex vivo transduction of HSPC 
with retroviral vectors led to clinical success but also some cases of leukaemia41. Lentiviral 
vectors display a safer integration pattern than gamma-retroviral vectors, and the SIN 
configuration also contributes to increasing bio-safety42. Additionally, high-efficiency 
lentiviral transduction can be achieved with IDLVs, produced through the use of integrase 
mutations that specifically prevent proviral integration, resulting in the generation of 
increased levels of circular vector episomes43 (Fig. 2A). Lacking replication signals, lentiviral 
episomes mediate transient transduction in dividing cells and stable expression in quiescent 
cells. We and others have shown efficient and sustained transgene expression in vivo in 
rodent ocular, cerebral and spinal cord tissues44-46, and substantial rescue of clinically 
relevant rodent models of retinal degeneration46 and Parkinson disease47. It is also possible 
to use retroviral vectors for so-called retrovirus particle-mediated mRNA transfer (RMT), 
whereby vector mutants unable to start reverse transcription are instead transiently 
translated48, and lentiviral vectors for protein delivery49. 
Future directions and hematopoietic application 
IDLVs have been shown to transiently transduce HSPC50. More recently, other applications 
for IDLVs have emerged (Fig. 2B-D). They can be used as platforms to deliver cassettes and 
zinc-finger nuclease genes for gene editing by homology-dependent repair in hematopoietic 
cells and others51, for transposition52 and for site-specific recombination53. Using the latter, 
IDLVs can yield site-specific recombination of a selectable donor cassette at the 'safe-
harbour' AAVS1 locus previously edited by zinc-finger nuclease to contain an acceptor site54. 
Dendritic cells are of particular interest and have been successfully targeted for transgenic 
expression with IDLVs55. An IDLV-based platform (ID-VP02) that targets and delivers antigen-
encoding nucleic acids to human dendritic cells has also been recently developed. It was 
constructed by incorporating a novel genetic variant of Sindbis virus envelope glycoprotein 
with posttranslational carbohydrate modifications in combination with Vpx, a SIVmac viral 
accessory protein56. Replicating IDLVs would be of considerable importance, and attempts to 
develop them have included the incorporation of the simian virus 40 (SV40) promoter/origin 
of replication in cells expressing SV40 large T-antigen57. A version of this vector incorporating 
HSV thymidine kinase allows suicide gene therapy using ganciclovir58. We have shown that 
replicating IDLVs can be established at high frequency by inducing transient cell-cycle arrest 
at the time of vector transduction, with no requirement for replication sequences59. 
 
Poxviral vectors, including vaccinia 
Poxviral vectors key features: 
• Large-capacity dsDNA viruses (>25 kb of foreign DNA). 
• Provide transient expression of immunologically relevant proteins. 
• Ability to activate appropriate innate immune mediators upon vaccination. 
• Relatively high-level of biological safety but potential for adverse events. 
Poxviruses have played an important role in the development of virology, immunology and 
vaccinology. Deliberate inoculation of cowpox virus to humans by Jenner in 1796 
demonstrated protection against the antigenically related smallpox virus (variola)60. 
Poxviruses are members of the family Poxviridae. They are dsDNA viruses about 200-400nm 
in length with a genome of about 190kb, which is flanked by ~10kb ITRs, and exist in two 
forms: an intracellular naked virion (INV) and an extracellular enveloped virion (EEV). 
Transcription and DNA replication occur in the cytoplasm, where the progeny DNA is 
generated by the synthesis and resolution of large concatemeric molecules60. Recombinant 
forms of the virus (with vaccinia as the prototype vector) are the vectors of choice for 
transient expression of immunologically relevant proteins61 and thus serve as an alternative 
approach to the development of vaccines against a variety of infectious agents (reviewed by 
Moss62). Recombinant poxviruses have the transgene of interest commonly inserted by 
homologous recombination and driven by a poxviral promoter rather than a constitutive 
viral or mammalian promoter, since they are cytoplasmatic viruses and encode their own 
RNA polymerase. Classical experiments showed that vaccinia can carry at least 25 kb of 
foreign DNA63. Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine 
against smallpox. Recombinant MVAs (rMVAs) can be used for protein production and as 
vaccines against infectious diseases, cancer and other pathologies64. 
Future directions and hematopoietic application 
Airway epithelial cells are the initial replication site of vaccinia virus, before spreading to 
secondary sites of infection, mainly the draining lymph nodes, spleen, gastrointestinal tract, 
and reproductive organs65. Stimulation of NK cell subsets during the antiviral response 
occurs through receptors apparently directed at viral products66. Understanding of the 
importance of NK cells in viral infections is improving, and poxviruses have been 
instrumental to improve this knowledge. After smallpox was eradicated, vaccinia has been 
used for the development of a variety of therapeutics: recombinant vaccines, 
immunotherapies, oncolytic therapies and others67. 
 
Other non-integrating viral vector systems 
No single viral vector is optimal for all potential gene therapy applications. The availability of 
many vector systems differing in cloning capacity, stability, tropism, immunogenicity and 
other properties provides options to target the tissue and strategy of interest. In addition to 
those reviewed above, a prominent place is also due to herpesvirus vectors, and particularly 
those based on HSV-1 for the purposes of gene transfer for cancer and neurodegenerative 
disease68. Sendai virus, an RNA virus with no risk of genomic integration that can infect a 
wide range of cell types including HSPC, has recently attracted significant interest. Sendai 
vectors have been used for delivery of CRISPR/Cas9 for efficient gene editing69, and for the 
generation of human induced pluripotent stem cells (iPSCs)70. 
 
Non-viral vectors 
Non-viral vectors key features: 
• Potentially unlimited packaging capacity. 
• Inexpensive to manufacture at GMP. 
• Can be endowed with replication and segregation capabilities for stable expression in 
proliferating cells. 
• Relatively inefficient delivery. 
• Relatively low immunogenicity. 
Non-viral vectors for gene delivery were amongst the earliest to be developed, starting with 
plasmids: Wilson et al. cloned the β-globin cDNA into a bacterial plasmid in 197871, and 
Green et al. successfully transfected the plasmid into cells by calcium phosphate co-
precipitation72. A distinctive feature of non-viral gene delivery is the ability to carry and 
deliver a broad range of nucleic acids. For gene addition studies, plasmids have been the 
most commonly used. However, more recently next-generation DNA molecules, including 
minicircle DNA73, mini-intronic plasmids74 and closed-ended linear duplex (CELiD) DNA75, 
have been developed that show both enhanced transgene expression and persistence 
compared to conventional plasmids. In addition to DNA, mRNA, siRNA and gRNA can also be 
delivered using non-viral vectors to provide short-term transgene expression, gene 
suppression and CRISPR/Cas genome editing, respectively. In the case of mRNA and siRNA, 
as they only need to enter the cytoplasm to function, nuclear entry is removed as a 
significant barrier to function. This can be particularly advantageous in non-dividing cells. 
The transient expression obtained with mRNA delivery is also useful for gene editing 
applications where expression and function of nucleases and transposons are needed for 
only a short period of time and where constitutive long-term expression could induce off-
target mutagenesis76.  
For large transgenes, or whole genes, human artificial chromosomes (HAC) are an option 
that can be utilised with non-viral vectors. HACs can carry entire genes, including their 
introns and be maintained in dividing cells as the artificial chromosomes are replicated and 
segregated with the host chromosomes. Yeast artificial chromosomes (YACs) with 200- to 
800-kilobase inserts of human DNA and first approaches to human mapping were described 
in the late 1980s77. Since these early days, applications of HACs have included development 
of transgenic mice with megabase-sized transgenes; stable maintenance in human 
embryonic stem cells; combination of human alpha satelite and single copy DNAs; and 
development of therapeutic human artificial chromosomes in preclinical models for 
Duchenne muscular dystrophy, caused by defects in the largest gene, DMD78. There is little 
consensus as to what constitutes a true 'artificial' versus an 'engineered' human 
chromosome, as recently reviewed79. However, the low efficiency of chromosome transfer 
and the relatively complex engineering of artificial chromosomes present significant 
challenges that have limited their utility as a therapeutic. 
A number of non-viral methods for nucleic acid delivery have been developed, which can be 
classified as physical or chemical. Physical methods include the use of ultrasound80 or 
electrical currents81 to temporarily increase the permeability of target cells (sonoporation 
and electroporation, respectively), direct injection of DNA into single cells82, ballistic 
propulsion of DNA-coated particles83 and hydrodynamic gene delivery involving the rapid 
injection of a large volume of DNA solution (8-10% of body weight)84. Gene delivery by 
physical methods is fairly simple but offers no protection from nucleases for the nucleic acid. 
In contrast, chemical carriers typically encapsulate nucleic acids thereby protecting the 
payload from nucleases. Chemical gene delivery vectors usually employ a cationic species to 
condense the anionic nucleic acids and in the process form nanoparticles for delivery. 
Cationic liposomes have been extensively studied and are among the most widely used non-
viral vectors85. Later, addition of cationic polymers (producing so-called lipopolyplex) was 
shown to enhance gene delivery86 (Fig. 3). Mechanistically, the liposome likely provides the 
mechanism for endosomal escape whilst the polymer enables efficient condensation and 
packaging of the nucleic acid therefore forming small, stable, discrete and homogenous 
nanoparticles. Further attempts at improving non-viral formulations have been made with 
the addition of components to improve bioavailability in vivo through shielding of complexes 
using polyethylene glycols, to enhance cell-specific targeting using targeting moieties, to aid 
endosomal escape using fusogenic lipids or pH sensitive polymers, and to improve nuclear 
entry using nuclear targeting sequences or nuclear localisation signal-containing peptides. 
 
Future directions and hematopoietic application 
The application of non-viral vectors to the hematopoietic system has been limited, but 
recent technologies are promising. T-cells can be genetically engineered to express a 
chimeric antigen receptor (CAR) using electroporation for sleeping beauty (SB) transposition, 
where SB was delivered as an mRNA or minicircle and the SB donor (consisting of the CAR 
sequences, flanked by SB inverted repeats) was provided as a minicircle87. Of importance, 
the integration pattern observed was considered safer than that present in CAR T-cells 
obtained with integrating lentiviral vector. Given the ease of scaling up production of mRNA 
and mini-circles and the close-to-random integration profile of SB transposition, there may 
be significant advantages to using non-viral methods for generating functional CAR T-cells. 
Novel electroporation technologies like nucleofection have also been reported to mediate 
efficient delivery of DNA, mRNA and siRNA to various hematopoietic cell lineages88. 
 
Concluding remarks 
HSPC have great therapeutic potential because of their ability to self-renew, differentiate 
and accomplish corrective reconstitution of the hematopoietic system in patients with 
various hematologic disorders. Specialised blood lineages are of relevance to specific 
strategies, like dendritic cells for immunisation or engineered CAR T-cells for lymphoma and 
leukaemia treatment. Gene addition therapies targeted to HSPC and using integrating 
retroviral vectors-have shown clear clinical benefits and potential in multiple diseases, 
among them immune deficiencies, storage disorders and hemoglobinopathies. However, the 
potential for insertional mutagenesis remains a risk. Gene editing technologies are also 
undergoing massive expansion and optimised, transient delivery is of clear benefit. The 
development of non-integrating nucleic acid delivery methods that combine low or no 
genotoxicity and high efficiency in hematopoietic cells is therefore highly desirable. We have 
described several such methods using Ad, AAV, IDLV, poxviral and non-viral vector 
technologies and are optimistic regarding the potential of non-integrating vectors in gene 
and stem cell therapy-based regenerative medicine. 
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FIGURE LEGENDS 
Figure 1. Diagrammatic representation of the basic genome structure of commonly used 
viruses and derived non-integrating vector constructs for gene therapy applications. 
Adenoviral (1st generation and helper-dependent), AAV and lentiviral vector structures are 
illustrated. Diagrams are not to scale. A & B: Adenovirus and Ad-based gene transfer vectors. 
The capacity of [E1-] Ad vectors is further increased by deletion of E3. HD Ad vectors contain 
the expression cassette of interest and ~500 bp of viral sequences required for DNA 
replication and packaging sequences. The ‘stuffer’ fragments are important for vector 
stability. C & D: wt AAV and recombinant AAV vector with expression transgene cassette 
flanked by ITRs; E &F: Lentiviral provirus and gene transfer vectors. Integrating lentiviral 
vectors (LVs) and IDLVs are produced similarly but for the latter the packaging plasmid 
encodes a mutated version of the integrase gene. ITR, inverted terminal repeat; Ψ, 
encapsidation sequence; pA, polyadenylation signal; LTR, long terminal repeat; SD, splice 
donor; SA, splice acceptor; cPPT, central polypurine tract; RRE, rev response element. 
 
Figure 2. Generation and uses of integration-deficient lentiviral vectors. A: Following reverse 
transcription of the lentiviral genome, double-stranded DNA present in the cytoplasm is 
translocated into the nucleus. In the absence of catalytically active integrase, proviral 
integration is minimized and increased levels of transcription-proficient viral episomes are 
generated by non-homologous end-joining mediated self-ligation and homologous 
recombination of dLTR sequences. dLTR: 5’-deleted self-inactivating LTR. B: Genome editing 
using IDLV-mediated template delivery. In the presence of an engineered chimeric nuclease 
able to cut the target locus (thin black arrow), efficient homology-dependent repair can take 
place, repairing a mutant gene. The mutation is represented as an orange signpost. C: IDLV-
mediated transposon delivery. Co-introduction of a transposase like sleeping beauty or 
piggybac and the corresponding transposon allows efficient transposition into the target cell 
genome. TA: di-nucleotide targeted by sleeping beauty and flanking the inserted transposon. 
Inverted orange arrows: transposon cis-acting sequences. D: IDLV-mediated site-specific 
integration. An IDLV containing a site-specific recombination cassette can be integrated at 
the target genomic site in the presence of the relevant integrase. Examples are flp-mediated 
recombination at FRT sites and cre-mediated recombination at loxP sites. The recombination 
site is represented as a black arrow. Note that in B-D genes encoding engineering nuclease, 
transposase or site-specific recombinase can also be delivered with IDLVs. 
 
Figure 3. Diagrammatic representation of barriers to non-viral transfection. Red arrows show 
limiting steps for lipoplex and polyplex technologies, potentially overcome by the use of 
lipopolyplex complexes. 
  
 Vector 
Gene Therapy Clinical Trials Worldwide 
Number % 
Adeno-associated virus 173 7.2 
Adenovirus 505 21.0 
Adenovirus + Modified vaccinia Ankara virus (MVA) 11 0.5 
Adenovirus + *Retrovirus 3 0.1 
Adenovirus + Sendai virus 1 0.0 
Adenovirus + Vaccinia virus 8 0.3 
Alphavirus (VEE) Replicon Vaccine 1 0.0 
Antisense oligonucleotide 6 0.2 
Bifidobacterium longum 1 0.0 
Escherichia coli 2 0.1 
Flavivirus 8 0.3 
Gene gun 5 0.2 
Herpes simplex virus 89 3.7 
Lactococcus lactis 6 0.2 
*Lentivirus 144 6.0 
Lipofection 115 4.8 
Listeria monocytogenes 22 0.9 
Measles virus 10 0.4 
Modified Vaccinia Ankara virus (MVA) 7 0.3 
mRNA Electroporation 5 0.2 
Naked/Plasmid DNA 414 17.2 
Naked/Plasmid DNA + Adenovirus 4 0.2 
Naked/Plasmid DNA + Modified Vaccinia Ankara virus (MVA) 2 0.1 
Naked/Plasmid DNA + RNA transfer 1 0.0 
Naked/Plasmid DNA + Vaccinia virus 3 0.1 
Naked/Plasmid DNA + Vesicular stomatitis virus 3 0.1 
Newcastle disease virus 1 0.0 
Non-viral 2 0.1 
Poliovirus 3 0.1 
Poxvirus 70 2.9 
Poxvirus + Vaccinia virus 36 1.5 
*Retrovirus 449 18.6 
RNA transfer 43 1.8 
RNA virus 5 0.2 
Saccharomyces cerevisiae 9 0.4 
Salmonella typhimurium 4 0.2 
Self-adjuvanting RNA 1 0.0 
Semliki forest virus 2 0.1 
Sendai virus 4 0.2 
Shigella dysenteriae 1 0.0 
*Simian Immunodeficiency Virus (SIVagm) 1 0.0 
Simian virus 40 1 0.0 
siRNA 5 0.2 
*Sleeping Beauty transposon 10 0.4 
Streptococcus mutans 1 0.0 
Vaccinia virus 125 5.2 
Venezuelan equine encephalitis virus replicon 3 0.1 
Vesicular stomatitis virus 3 0.1 
Vibrio cholerae 1 0.0 
Unknown 80 3.3 
Total 2409 100% 
 
Table 1. Clinical trials using Non-Integrating Viral and Non-Viral vectors. To date at least 
71.5% (1722 trials of a total 2409 registered) of the clinical trials reported have used non-
integrating viral and/or non-viral vectors. Blue: non-integrating vectors; red: integrating 
vector or mixture (* indicates integrating vector); black, unknown. Adapted from the Journal 
of Gene Medicine, Gene Therapy Clinical Trials Worldwide, Wiley Database, (August 2016). 
http://www.abedia.com/wiley/vectors.php 
  
Vector 
Carrying 
Capacity 
(kb) 
Features Advantages Disadvantages 
Initial 
applications 
Adenoviru
s 
~8-30 
Nuclear 
Episome 
Efficient 
delivery to 
dividing and 
non-dividing 
cells 
High, but 
transient 
expression 
High Immunogenicity 
Cancer 
Therapeutics 
Vaccination 
AAV ~4.5 
Episomal 
concatemer
s 
Efficient 
delivery to 
dividing and 
non-dividing 
cells 
Relatively low 
immunogenicit
y 
Possible long-term 
persistence of capsids 
in vivo 
Potential for 
encapsidation of 
prokaryotic 
sequences 
Efficient and 
persistent in 
vivo delivery to 
post-mitotic 
tissues  
Delivery of gene 
editing 
components 
IDLV ~7.5 
Mutations 
of integrase 
gene in 
packaging 
plasmid 
Efficient 
delivery to 
dividing and 
non-dividing 
cells 
Transient 
expression in 
proliferating 
cells and 
sustained 
expression in 
post-mitotic 
tissues 
Relatively low 
immunogenicit
y 
Low expression in 
proliferating cells 
Vaccination 
Delivery of gene 
editing 
templates 
Poxvirus >25 
Poxviral RNA 
pol-based 
Large capacity 
Delivery of 
substantial 
cassettes of 
heterologous 
antigens 
Activates innate 
immune 
mediators 
Potential for adverse 
events, particularly in 
immunocompromise
d patients 
Transient 
expression of 
immunologicall
y relevant 
proteins 
Vaccination 
Non-Viral 
Potentiall
y 
Unlimited 
Chemical 
formulation 
Inexpensive to 
manufacture 
Can achieve 
stable 
expression with 
replication and 
segregation 
Relatively inefficient 
delivery 
Gene delivery 
to muscle 
Table 2. Properties of Non-Integrating Gene Therapy Vectors.  
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